Q-omics provides the consensus-scored RPS11P7 profile across patient tissues and cancer cell-line models. RPS11P7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RPS11P7 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RPS11P7 RNA expression shows 6,156 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight CHOL, COAD, and UCEC as cancer lineages where RPS11P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS11P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS11P7 survival associations across molecular data types. RPS11P7 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS11P7 RNA expression–survival associations across cancer types. High RPS11P7 expression shows unfavorable associations in CHOL, PAAD and MESO, but favorable associations in KIRC, HNSC and LIHC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for RPS11P7 RNA expression.
This table summarizes RPS11P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS11P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS11P7 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, LIHC and PRAD. The COAD box plot shows higher RPS11P7 RNA expression in tumor versus normal tissue (log2 FC = +0.897, t-test p < 0.001).
This table shows molecular features associated with RPS11P7 in patient tissues and cancer cell lines. In patient samples, RPS11P7 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
